Comparison of plasma homocysteine levels in patients with type 2 diabetes mellitus with normal subjects

Yıl 2012, , 235 - 239, 01.06.2012

İsmail Erşan Banu Turgut Öztürk Ümit Kamış Ahmet Özkağnıcı Kemal Gündüz

https://doi.org/10.5799/ahinjs.01.2012.02.0150

Öz

Objectives: To compare the plasma homocysteine levels between control group and diabetic patients with no diabetic retinopathy, with preproliferative diabetic retinopathy, with proliferative diabetic retinopathy. Materials and methods: Plasma homocysteine levels of 23 diabetic patients were measured and were compared with 25 age-matched controls with no systemic problem and no ocular disease. Plasma homocysteine levels were measured using high-performance liquid chromatography. Results: Diabetic patients were divided into three groups according to their ophthalmological findings. There were 8 patients with no diabetic retinopathy, 8 patients with preproliferative diabetic retinopathy, 7 patients with proliferative diabetic retinopathy. Plasma homocysteine levels were higher in diabetic patients (13.30±4.03 µmol/L) compared to the control group (11.71±3.41 µmol/L) but no statistically significant difference was found between the two groups (p>0.05). Plasma homocysteine levels were measured 12.50±3.73 µmol/L in no diabetic retinopathy group, 12.90±2.59 µmol/L in preproliferative diabetic retinopathy group, 14.64±5.69 µmol/L in proliferative diabetic retinopathy group. In diabetic group, plasma homocysteine levels increased with the increase of the severity of retinopathy but not reached statistically significance (p>0.05). Conclusion: Although no statistically significance was found, retinopathy progresses with the increase of plasma homocysteine levels. This can be used for the follow-up of the diabetic patients but further evaluation in large groups is needed. J Clin Exp Invest 2012; 3(2): 235-239

Anahtar Kelimeler

Homocysteine, diabetes mellitus, diabetic retinopathy

Tip 2 diabetes mellituslu hastalarda plazma homosistein düzeyinin normal popülasyonla karşılaştırılması

Öz

Amaç: Preproliferatif ve proliferatif diabetik retinopatili
hastalar ile retinopatisi olmayan diabetes mellitus hastalarının
plazma homosistein düzeylerinin normal popülasyonla
karşılaştırılması amaçlanmıştır.
Gereç ve yöntem: Tip 2 diabet 23 hastanın plazma homosistein
düzeyleri ile benzer yaş grubunda, herhangi bir
sistemik hastalığı ve oküler problemi olmayan 25 olgunun
plazma homosistein düzeyleri karşılaştırıldı. Homosistein
düzeyi yüksek performanslı sıvı kromatografi yöntemi ile
ölçüldü.
Bulgular: Diabetes mellituslu olgular fundus muayenelerine
göre üç gruba ayrıldı. 8 olguda diabetik retinopati
bulgusu olmadığı, 8’inde preproliferatif, 7’sinde proliferatif
diabetik retinopati olduğu saptandı. Plazma homosistein
düzeyi diabetes mellituslu grupta (ortalama 13,30±4,03
µmol/L), kontrol grubuna göre (ortalama 11,71±3,41
µmol/L) yüksek olmakla birlikte her iki grup arasında istatistiksel
olarak anlamlı fark bulunmadı (p > 0,05). Diabetes
mellituslu grup içinde ise diabetik retinopatisi olmayan
grupta plazma homosistein düzeyi ortalaması 12,50±3,73
µmol/L iken, preproliferatif diabetik retinopati grubunda
ortalama 12,90±2,59 µmol/L; proliferatif diabetik retinopatisi
olan grupta ise ortalama 14,64±5,69 µmol/L düzeyinde
saptandı. Ortalama plazma homosistein düzeyi retinopatinin
ilerlemesiyle artış göstermekle birlikte bulguların istatistiksel
analizinde bu artış anlamlı bulunmadı (p > 0,05).
Sonuç: İstatistiksel olarak anlamlı olmamakla birlikte
plazma homosistein düzeyinin özellikle retinopati ilerledikçe
artması plazma homosistein düzeyinin tip 2 diabetes
mellituslu olguların takibinde kullanılabileceğini ancak
daha büyük çalışma gruplarının daha kesin bilgi verebileceğini
düşündürmektedir.

Anahtar Kelimeler

Homosistein, diabetes mellitus, diabetik retinopati

Kaynakça

• Kempen JH, O’Colmain BJ, Leske MC, et al. Eye Diseases Prevalence Research Group: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122(4):552-63.
• Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW. How the diabetic eye loses vision. Endocrine 2007;32(1):107-16.
• Castro R, Rivera I, Blom HJ, Jakobs C, de Almeida IT. Homocysteine metabolism, hyperhomocysteinemia and vascular disease: an overview. J Inherit Metab Dis 2006;29(1):3-20.
• Clarke R, Daly L, Robinson K, et al. Hyperhomocyşteinemia: An independent risk factor for vascular disease. N Engl J Med 1991;324(17):114955.
• Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM. Plasma homocysteine as a risk factor tor vascular disease. The European Concerted Action Project. JAMA 1997;277(22):1775-81.
• Stampfer MJ, Malinow MR,Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardiaI infarction in US physicians. JAMA 1992; 268(7): 877-81.
• Pery I, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middleaged British men. Lancet 1995;346(8987):1395-8.
• Lieberman TW, Podos SM, Hartstein J. Acute glaucoma, ectopia lentis and omocystinuria. Am J Ophthalmol 1966;61(2):252-5.
• Stanger O, Weger M, Obeid R, et al. Impairment of homocysteine metabolism in patients with retinal vascular occlusion and nonarteritic ischemic optic neuropathy. Clin Chem Lab Med 2005;43(10):1020-5.
• Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993;115(2):162-7.
• Coral K, Raman R, Rathi S, et al. Plasma homocysteine and total thiol content in patients with exudative agerelated macular degeneration. Eye 2006;20(2):203-7.
• Brazionis L, Rowley K Sr, Itsiopoulos C, Harper CA, O’Dea KK. Homocysteine and diabetic retinopathy. Diab Care 2008;31(1):50-6.
• Hofmann MA, Kohl B, Zumbach MS, et al. Hyperhomocysteinemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21(5):841-8.
• Vaccaro O, Perna AF, Mancini FP, et all. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000;10(6);297304.
• Kark JD, Selhub J, Bostom A, Adler B, Rosenberg IH. Plasma homocysteine and all-cause mortality in diabates. Lancet 1999;353(9168):1936-7.
• Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes. 5-year follow-up of the Hoorn study. Circulation 2000;101(13):1506-11.
• Hoogeveen EK, Kostense PJ, Eysink PE, et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 2000;160(19):2984-90.
• Goldstein M, Leibovitch I, Yeffimov I, Gavendo S, Sela BA, Loewenstein A. Hyperhomocsteinemia in diabetes mellitus with and without diabetic retinopathy. Eye 2004;18(5):460-5.
• Aydin E, Demir HD, Ozyurt H, Etikan I. Association of plasma homocysteine and macular edema in type 2 diabetes mellitus. Eur J Ophthalmol 2008;18(2):22632.
• Aydemir O, Türkcüoğlu P, Güler M, et al. Plasma and vitreous homocysteine concentrations in patients with proliferative diabetic retinopathy. Retina. 2008;28(5):741-3.
• Raposo B, Rodríguez C, Martínez-Gonza´lez J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. Atherosclerosis 2004;177(1):18.
• Coral K, Angayarkanni N, Gomathy N, et al. Homocysteine levels in the vitreous of proliferative diabetic retinopathy and rhegmatogenous retinal detachment: its modulating role on lysyl oxidase. Invest Ophthalmol Vis Sci 2009;50(8):3607-12.
• Kim HJ, Kim MK, Kim JU, Ha HY, Choi BY. Major determinants of serum homocysteine concentrations in a Korean population. J Korean Med Sci 2010;25(4):50916.
• Saw SM, Yuan JM, Ong CN, et al. Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr 2001;73(2):232-9.